NASDAQ:INSY - Insys Therapeutics Stock Price, Price Target & More

$7.09 +0.33 (+4.88 %)
(As of 04/19/2018 08:07 AM ET)
Previous Close$6.76
Today's Range$6.70 - $7.32
52-Week Range$4.10 - $15.02
Volume1.04 million shs
Average Volume1.26 million shs
Market Capitalization$498.95 million
P/E Ratio-14.47
Dividend YieldN/A
Beta1.13

About Insys Therapeutics (NASDAQ:INSY)

Insys Therapeutics logoInsys Therapeutics, Inc. is a commercial-stage specialty pharmaceutical company. The Company develops and commercializes supportive care products. The Company's product Subsys, is a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and a single-use product that delivers fentanyl, an opioid analgesic, for transmucosal absorption underneath the tongue. The Company markets Subsys through its field sales force focused on supportive care physicians in the United States. Subsys delivers a liquid fentanyl formulation in approximately 100, 200, 400, 600, 800, 1,200 and 1,600 micrograms (mcg) dosages. The Company's lead dronabinol product candidate is Syndros, which is under review for approval at the Food and Drug Administration. In addition, the Company is evaluating sublingual spray, inhaled and intravenous formulations of dronabinol in preclinical studies.

Receive INSY News and Ratings via Email

Sign-up to receive the latest news and ratings for INSY and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:INSY
CUSIPN/A
Phone480-500-3127

Debt

Debt-to-Equity RatioN/A
Current Ratio0.85%
Quick Ratio0.77%

Price-To-Earnings

Trailing P/E Ratio-14.47
Forward P/E Ratio-8.54
P/E GrowthN/A

Sales & Book Value

Annual Sales$140.69 million
Price / Sales3.72
Cash FlowN/A
Price / CashN/A
Book Value$0.86 per share
Price / Book8.24

Profitability

EPS (Most Recent Fiscal Year)($0.49)
Net Income$-228,010,000.00
Net Margins-162.07%
Return on Equity-24.02%
Return on Assets-13.23%

Miscellaneous

Employees343
Outstanding Shares73,810,000

How to Become a New Pot Stock Millionaire

Insys Therapeutics (NASDAQ:INSY) Frequently Asked Questions

What is Insys Therapeutics' stock symbol?

Insys Therapeutics trades on the NASDAQ under the ticker symbol "INSY."

When did Insys Therapeutics' stock split? How did Insys Therapeutics' stock split work?

Insys Therapeutics's stock split on Monday, March 31st 2014. The 3-2 split was announced on Tuesday, March 4th 2014. The newly issued shares were issued to shareholders after the market closes on Friday, March 28th 2014. An investor that had 100 shares of Insys Therapeutics stock prior to the split would have 150 shares after the split.

How were Insys Therapeutics' earnings last quarter?

Insys Therapeutics (NASDAQ:INSY) released its earnings results on Thursday, March, 8th. The specialty pharmaceutical company reported ($0.61) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.14) by $0.47. The specialty pharmaceutical company earned $31.49 million during the quarter, compared to analyst estimates of $34 million. Insys Therapeutics had a negative net margin of 162.07% and a negative return on equity of 24.02%. The company's revenue was down 42.6% on a year-over-year basis. During the same quarter last year, the company earned $0.03 earnings per share. View Insys Therapeutics' Earnings History.

What price target have analysts set for INSY?

5 equities research analysts have issued 1-year target prices for Insys Therapeutics' stock. Their forecasts range from $8.00 to $11.00. On average, they anticipate Insys Therapeutics' stock price to reach $9.6667 in the next twelve months. View Analyst Ratings for Insys Therapeutics.

Who are some of Insys Therapeutics' key competitors?

Who are Insys Therapeutics' key executives?

Insys Therapeutics' management team includes the folowing people:
  • Steven J. Meyer, Independent Chairman of the Board (Age 60)
  • Saeed Motahari, President, Chief Executive Officer, Director (Age 51)
  • Andrew G. Long, Chief Financial Officer
  • Venkat R. Goskonda, Senior Vice President - Research & Development
  • Steve Sherman, Senior Vice President - Regulatory Affairs
  • Franc Del Fosse, General Counsel, Corporate Secretary (Age 45)
  • Rohit Vishnoi, Director
  • Pierre Lapalme, Independent Director (Age 76)
  • Vaseem Mahboob, Independent Director (Age 48)
  • Brian Tambi, Independent Director (Age 71)

Has Insys Therapeutics been receiving favorable news coverage?

News headlines about INSY stock have been trending somewhat positive recently, according to Accern Sentiment Analysis. Accern identifies positive and negative news coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Insys Therapeutics earned a coverage optimism score of 0.17 on Accern's scale. They also assigned press coverage about the specialty pharmaceutical company an impact score of 45.80 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the near term.

How do I buy shares of Insys Therapeutics?

Shares of INSY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Insys Therapeutics' stock price today?

One share of INSY stock can currently be purchased for approximately $7.09.

How big of a company is Insys Therapeutics?

Insys Therapeutics has a market capitalization of $498.95 million and generates $140.69 million in revenue each year. The specialty pharmaceutical company earns $-228,010,000.00 in net income (profit) each year or ($0.49) on an earnings per share basis. Insys Therapeutics employs 343 workers across the globe.

How can I contact Insys Therapeutics?

Insys Therapeutics' mailing address is 1333 S. Spectrum Blvd Suite 100, Chandler AZ, 85286. The specialty pharmaceutical company can be reached via phone at 480-500-3127 or via email at [email protected]


MarketBeat Community Rating for Insys Therapeutics (INSY)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  314 (Vote Outperform)
Underperform Votes:  226 (Vote Underperform)
Total Votes:  540
MarketBeat's community ratings are surveys of what our community members think about Insys Therapeutics and other stocks. Vote "Outperform" if you believe INSY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe INSY will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Insys Therapeutics (NASDAQ:INSY) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
5 Wall Street analysts have issued ratings and price targets for Insys Therapeutics in the last 12 months. Their average twelve-month price target is $9.6667, suggesting that the stock has a possible upside of 36.34%. The high price target for INSY is $11.00 and the low price target for INSY is $8.00. There are currently 1 sell rating, 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldBuyBuy
Consensus Rating Score: 2.202.202.502.50
Ratings Breakdown: 1 Sell Rating(s)
2 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
2 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $9.6667$9.6667$9.6667$12.6667
Price Target Upside: 36.34% upside29.23% upside87.34% upside61.36% upside

Insys Therapeutics (NASDAQ:INSY) Consensus Price Target History

Price Target History for Insys Therapeutics (NASDAQ:INSY)

Insys Therapeutics (NASDAQ:INSY) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/11/2018OppenheimerReiterated RatingHoldMediumView Rating Details
3/9/2018Piper JaffrayDowngradeNeutral -> UnderweightHighView Rating Details
3/2/2018CannReiterated RatingAverageHighView Rating Details
11/3/2017Jefferies GroupLower Price TargetBuy$14.00 -> $11.00N/AView Rating Details
10/27/2017Royal Bank of CanadaSet Price TargetBuy$8.00N/AView Rating Details
(Data available from 4/19/2016 forward)

Earnings

Insys Therapeutics (NASDAQ:INSY) Earnings History and Estimates Chart

Earnings by Quarter for Insys Therapeutics (NASDAQ:INSY)

Insys Therapeutics (NASDAQ:INSY) Earnings Estimates

Current Year EPS Consensus Estimate: $-0.83 EPS
Next Year EPS Consensus Estimate: $-0.49 EPS

Insys Therapeutics (NASDAQ INSY) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/8/2018Q4 2017($0.14)($0.61)$34.00 million$31.49 millionViewListenView Earnings Details
11/2/2017Q3 2017($0.23)($0.25)$34.98 million$30.67 millionViewN/AView Earnings Details
8/3/2017Q2 2017($0.09)$0.03$36.90 million$42.60 millionViewListenView Earnings Details
5/9/2017Q1 2017($0.10)($0.09)$37.78 million$35.92 millionViewListenView Earnings Details
4/3/2017Q4 2016($0.0020)$0.03$52.08 million$54.86 millionViewN/AView Earnings Details
11/3/2016Q316$0.02$0.07$55.97 million$55.20 millionViewN/AView Earnings Details
8/3/2016Q216$0.07$0.06$66.90 million$67.10 millionViewListenView Earnings Details
4/28/2016Q116$0.07$0.11$61.31 million$62.00 millionViewListenView Earnings Details
2/23/2016Q415$0.29$0.36$91.04 million$91.10 millionViewListenView Earnings Details
11/5/2015Q315$0.23$0.50$82.98 million$91.30 millionViewN/AView Earnings Details
8/6/2015Q215$0.21$0.16$74.06 million$77.60 millionViewN/AView Earnings Details
5/7/2015Q115$0.40$0.63$70.90 million$70.80 millionViewN/AView Earnings Details
3/3/2015Q414$0.44$0.53$63.50 million$66.50 millionViewN/AView Earnings Details
11/11/2014Q314$0.29$0.63$57.10 million$58.30 millionViewN/AView Earnings Details
8/12/2014Q214$0.30$0.48$52.77 million$55.70 millionViewN/AView Earnings Details
5/13/2014Q1 2014$0.14$0.18$46.00 million$41.64 millionViewN/AView Earnings Details
3/4/2014Q413$0.55$0.71$34.73 million$40.20 millionViewN/AView Earnings Details
11/12/2013Q3$0.33$0.58$27.00 million$29.20 millionViewListenView Earnings Details
8/13/2013Q213$0.12$0.35$15.07 million$18.80 millionViewN/AView Earnings Details
6/3/2013Q113$0.01$2.00 million$11.10 millionViewN/AView Earnings Details
8/26/2010Q2 2010($0.59)ViewN/AView Earnings Details
6/11/2010Q1 2010($1.02)ViewN/AView Earnings Details
3/18/2010Q4 2009($0.33)ViewN/AView Earnings Details
10/26/2009Q3 2009($1.26)ViewN/AView Earnings Details
7/27/2009Q2 2009($1.42)ViewN/AView Earnings Details
4/28/2009Q1 2009($1.61)ViewN/AView Earnings Details
3/4/2009Q4 2008($1.59)ViewN/AView Earnings Details
11/12/2008Q3 2008($1.71)ViewN/AView Earnings Details
8/14/2008Q2 2008($1.48)ViewN/AView Earnings Details
5/12/2008Q1 2008($1.08)ViewN/AView Earnings Details
3/27/2008Q4 2007($0.75)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Insys Therapeutics (NASDAQ:INSY) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Insys Therapeutics (NASDAQ INSY) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 67.90%
Institutional Ownership Percentage: 24.05%
Insider Trading History for Insys Therapeutics (NASDAQ:INSY)
Institutional Ownership by Quarter for Insys Therapeutics (NASDAQ:INSY)

Insys Therapeutics (NASDAQ INSY) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/11/2017John N Kapoor Trust Dated SeptMajor ShareholderBuy17,500$8.93$156,275.0031,982View SEC Filing  
8/10/2017Saeed MotahariCEOBuy5,500$8.92$49,060.0015,400View SEC Filing  
6/14/2017Saeed MotahariCEOBuy5,400$11.10$59,940.009,900View SEC Filing  
6/1/2017Rohit VishnoiDirectorBuy4,000$14.14$56,560.004,000View SEC Filing  
5/18/2017Steven J MeyerDirectorBuy8,000$12.21$97,680.0052,083View SEC Filing  
5/16/2017Saeed MotahariCEOBuy4,500$11.98$53,910.004,500View SEC Filing  
11/4/2016Steven J MeyerDirectorBuy10,000$10.75$107,500.0044,083View SEC Filing  
8/16/2016Theodore H StanleyDirectorSell15,000$18.02$270,300.0017,000View SEC Filing  
8/12/2016John N Kapoor Trust Dated SeptMajor ShareholderBuy5,700$18.57$105,849.0031,982View SEC Filing  
8/11/2016Patrick FourteauDirectorSell15,000$18.46$276,900.0049,682View SEC Filing  
8/9/2016Daniel BrennanVPSell5,781$19.16$110,763.961View SEC Filing  
6/6/2016Theodore H StanleyDirectorSell16,000$16.27$260,320.0018,000View SEC Filing  
5/12/2016John N Kapoor Trust Dated SeptMajor ShareholderBuy50,000$12.84$642,000.0031,982View SEC Filing  
3/4/2016Patrick FourteauDirectorSell15,000$18.22$273,300.0064,682View SEC Filing  
11/17/2015John N Kapoor Trust Dated SeptMajor ShareholderBuy5,000$29.50$147,500.0031,982View SEC Filing  
11/12/2015John N Kapoor Trust Dated SeptMajor ShareholderBuy10,000$26.58$265,800.0031,982View SEC Filing  
11/12/2015Patrick FourteauDirectorSell30,000$26.48$794,400.0079,682View SEC Filing  
9/14/2015Theodore H. StanleyDirectorSell4,000$37.04$148,160.002,000View SEC Filing  
6/10/2015Fosse Franc DelGeneral CounselSell10,000$34.48$344,800.00View SEC Filing  
6/5/2015Steven J MeyerDirectorSell5,000$63.00$315,000.00View SEC Filing  
5/27/2015Brian TambiDirectorSell3,100$60.09$186,279.00View SEC Filing  
5/26/2015Brian TambiDirectorSell1,800$60.00$108,000.00View SEC Filing  
5/20/2015Patrick FourteauDirectorSell9,064$60.00$543,840.00View SEC Filing  
5/18/2015Darryl S BakerCFOSell10,000$59.17$591,700.00View SEC Filing  
5/11/2015Steven J MeyerDirectorSell18,000$57.06$1,027,080.00View SEC Filing  
3/17/2015Michael L BabichCEOSell75,000$58.63$4,397,250.00View SEC Filing  
3/11/2015Patrick FourteauDirectorSell10,000$59.94$599,400.00View SEC Filing  
3/10/2015Theodore H StanleyDirectorSell3,300$60.03$198,099.00View SEC Filing  
2/9/2015Darryl S BakerCFOSell30,000$52.23$1,566,900.00View SEC Filing  
11/19/2014Patrick FourteauDirectorSell25,000$39.11$977,750.00View SEC Filing  
11/4/2014Michael L BabichCEOSell80,000$38.66$3,092,800.00View SEC Filing  
8/13/2014Theodore H StanleyDirectorBuy3,000$33.93$101,790.00View SEC Filing  
6/16/2014John N KapoorDirectorBuy5,000$26.13$130,650.00View SEC Filing  
6/13/2014John N KapoorDirectorBuy5,000$25.44$127,200.00View SEC Filing  
6/12/2014John N KapoorDirectorBuy20,000$24.84$496,800.00View SEC Filing  
6/11/2014John N KapoorDirectorBuy20,000$24.54$490,800.00View SEC Filing  
5/19/2014Theodore StanleyDirectorBuy4,000$21.94$87,760.006,100View SEC Filing  
5/15/2014Patrick FourteauDirectorBuy7,500$22.77$170,775.00105,000View SEC Filing  
3/5/2014Larry DillahaInsiderSell149,932$74.57$11,180,429.243,125View SEC Filing  
3/5/2014Michael BabichCEOSell288,432$74.58$21,511,258.565,375View SEC Filing  
1/16/2014Darryl BakerCFOSell10,000$49.61$496,100.003,125View SEC Filing  
1/15/2014Darryl BakerCFOSell10,000$47.54$475,400.003,125View SEC Filing  
1/14/2014Darryl BakerCFOSell10,000$45.64$456,400.003,125View SEC Filing  
12/9/2013John KapoorDirectorSell27,428$47.25$1,295,973.00View SEC Filing  
8/16/2013Michael BabichCEOBuy1,000$24.90$24,900.0078,557View SEC Filing  
8/14/2013Patrick FourteauDirectorBuy5,000$23.77$118,850.0065,000View SEC Filing  
6/4/2013Michael L BabichCEOBuy1,250$10.93$13,662.50View SEC Filing  
5/24/2013Pierre LapalmeDirectorBuy3,000$10.39$31,170.00View SEC Filing  
5/14/2013Patrick FourteauDirectorBuy5,000$10.90$54,500.00View SEC Filing  
5/13/2013Patrick FourteauDirectorBuy4,800$10.90$52,320.00View SEC Filing  
5/7/2013Patrick FourteauDirectorBuy50,000$8.36$418,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Insys Therapeutics (NASDAQ INSY) News Headlines

Source:
DateHeadline
Insys Therapeutics (INSY) Upgraded by Zacks Investment Research to "Strong-Buy"Insys Therapeutics (INSY) Upgraded by Zacks Investment Research to "Strong-Buy"
www.americanbankingnews.com - April 18 at 10:16 PM
BRIEF-Insys Therapeutics To Advance Clinical Research Of Dronabinol Inhalation Using Novel Breath-Actuated DeviceBRIEF-Insys Therapeutics To Advance Clinical Research Of Dronabinol Inhalation Using Novel Breath-Actuated Device
www.reuters.com - April 18 at 3:21 PM
INSYS to advance research on dronabinol inhalation via novel device; shares up 6%INSYS to advance research on dronabinol inhalation via novel device; shares up 6%
seekingalpha.com - April 18 at 3:21 PM
INSYS Therapeutics to Advance Clinical Research of Dronabinol Inhalation Using Novel Breath-Actuated DeviceINSYS Therapeutics to Advance Clinical Research of Dronabinol Inhalation Using Novel Breath-Actuated Device
finance.yahoo.com - April 18 at 3:21 PM
Drug Made From Cannabis Plant Gets Backing From FDA StaffDrug Made From Cannabis Plant Gets Backing From FDA Staff
finance.yahoo.com - April 17 at 10:31 AM
Insys Therapeutics (INSY) Lowered to Hold at BidaskClubInsys Therapeutics (INSY) Lowered to Hold at BidaskClub
www.americanbankingnews.com - April 16 at 9:48 AM
Insys Therapeutics (INSY) Expected to Post Quarterly Sales of $26.09 MillionInsys Therapeutics (INSY) Expected to Post Quarterly Sales of $26.09 Million
www.americanbankingnews.com - April 16 at 4:19 AM
Insys Therapeutics (INSY) Given a $10.00 Price Target by Piper Jaffray AnalystsInsys Therapeutics (INSY) Given a $10.00 Price Target by Piper Jaffray Analysts
www.americanbankingnews.com - April 15 at 11:42 PM
Insys Therapeutics Inc (INSY) Expected to Post Earnings of -$0.19 Per ShareInsys Therapeutics Inc (INSY) Expected to Post Earnings of -$0.19 Per Share
www.americanbankingnews.com - April 14 at 7:41 AM
Oppenheimer Reiterates "Hold" Rating for Insys Therapeutics (INSY)Oppenheimer Reiterates "Hold" Rating for Insys Therapeutics (INSY)
www.americanbankingnews.com - April 13 at 10:53 AM
Will These Biotechs Light The Way For Cannabis-Based Drugs?Will These Biotechs Light The Way For Cannabis-Based Drugs?
finance.yahoo.com - April 13 at 8:28 AM
Insys Therapeutics (INSY) Rating Lowered to Hold at Zacks Investment ResearchInsys Therapeutics (INSY) Rating Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - April 11 at 6:43 PM
Insys Therapeutics Inc (INSY) Given Consensus Rating of "Hold" by AnalystsInsys Therapeutics Inc (INSY) Given Consensus Rating of "Hold" by Analysts
www.americanbankingnews.com - April 11 at 1:24 AM
Insys Therapeutics (INSY) Downgraded by TheStreetInsys Therapeutics (INSY) Downgraded by TheStreet
www.americanbankingnews.com - April 9 at 9:46 PM
Company blamed for fueling fentanyl addiction crisis will soon be approved to sell synthetic cannabisCompany blamed for fueling fentanyl addiction crisis will soon be approved to sell synthetic cannabis
www.msn.com - April 7 at 8:01 AM
Insys Therapeutics (INSY) Upgraded at Zacks Investment ResearchInsys Therapeutics (INSY) Upgraded at Zacks Investment Research
www.americanbankingnews.com - April 6 at 1:55 PM
Heres Why Insys Therapeutics Inc. Tanked 17% in MarchHere's Why Insys Therapeutics Inc. Tanked 17% in March
www.msn.com - April 5 at 3:20 PM
Here's Why Insys Therapeutics Inc. Tanked 17% in MarchHere's Why Insys Therapeutics Inc. Tanked 17% in March
finance.yahoo.com - April 5 at 3:20 PM
Insys blasts incredibly broad Maryland opioid probe subpoenaInsys blasts 'incredibly broad' Maryland opioid probe subpoena
www.reuters.com - April 5 at 9:29 AM
Insys Therapeutics (INSY) Upgraded to Sell at ValuEngineInsys Therapeutics (INSY) Upgraded to Sell at ValuEngine
www.americanbankingnews.com - April 3 at 11:31 PM
INSYS Therapeutics Appoints Trudy Vanhove to Board of DirectorsINSYS Therapeutics Appoints Trudy Vanhove to Board of Directors
finance.yahoo.com - April 2 at 3:21 PM
Zacks: Analysts Expect Insys Therapeutics Inc (INSY) Will Announce Quarterly Sales of $26.09 MillionZacks: Analysts Expect Insys Therapeutics Inc (INSY) Will Announce Quarterly Sales of $26.09 Million
www.americanbankingnews.com - March 30 at 3:52 AM
Zacks: Brokerages Expect Insys Therapeutics Inc (INSY) to Announce -$0.19 EPSZacks: Brokerages Expect Insys Therapeutics Inc (INSY) to Announce -$0.19 EPS
www.americanbankingnews.com - March 28 at 9:54 AM
Insys Therapeutics (INSY) Cut to "Strong Sell" at ValuEngineInsys Therapeutics (INSY) Cut to "Strong Sell" at ValuEngine
www.americanbankingnews.com - March 23 at 8:30 PM
Positive CBD Legislation Will Positively Impact These CompaniesPositive CBD Legislation Will Positively Impact These Companies
www.prnewswire.com - March 21 at 10:46 AM
Is Insys At Risk? - Seeking AlphaIs Insys At Risk? - Seeking Alpha
seekingalpha.com - March 20 at 3:26 PM
INSYS Therapeutics Reiterates Commitment to Compliant and Ethical Business Practices and Advancing Innovative ... - GlobeNewswire (press release)INSYS Therapeutics Reiterates Commitment to Compliant and Ethical Business Practices and Advancing Innovative ... - GlobeNewswire (press release)
globenewswire.com - March 19 at 3:22 PM
INSYS Therapeutics Reiterates Commitment to Compliant and Ethical Business Practices and Advancing Innovative Product PipelineINSYS Therapeutics Reiterates Commitment to Compliant and Ethical Business Practices and Advancing Innovative Product Pipeline
finance.yahoo.com - March 19 at 3:22 PM
Five New York doctors charged with taking kickbacks from Insys - ReutersFive New York doctors charged with taking kickbacks from Insys - Reuters
www.reuters.com - March 17 at 5:54 AM
Insys Therapeutics Inc (INSY) Receives Consensus Rating of "Hold" from AnalystsInsys Therapeutics Inc (INSY) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - March 17 at 1:36 AM
5 doctors charged with taking kickbacks to tout painkiller5 doctors charged with taking kickbacks to tout painkiller
marketbeat.com - March 16 at 4:19 PM
Five New York doctors charged with taking kickbacks from InsysFive New York doctors charged with taking kickbacks from Insys
finance.yahoo.com - March 16 at 3:17 PM
Insys Therapeutics (INSY) Upgraded at ValuEngineInsys Therapeutics (INSY) Upgraded at ValuEngine
www.americanbankingnews.com - March 14 at 11:22 PM
Is Beaten-Down Marijuana Stock Insys Therapeutics a Bad-News Buy?Is Beaten-Down Marijuana Stock Insys Therapeutics a Bad-News Buy?
finance.yahoo.com - March 13 at 3:24 PM
Ivy League Doctor Gets 4 Years in Prison for Insys Opioid Kickbacks - FortuneIvy League Doctor Gets 4 Years in Prison for Insys Opioid Kickbacks - Fortune
fortune.com - March 12 at 8:10 AM
Insys: Will The Pipeline Drive Future Growth? - Seeking AlphaInsys: Will The Pipeline Drive Future Growth? - Seeking Alpha
seekingalpha.com - March 12 at 8:10 AM
Insys Therapeutics (INSY) Hold Rating Reiterated at OppenheimerInsys Therapeutics' (INSY) Hold Rating Reiterated at Oppenheimer
www.americanbankingnews.com - March 11 at 6:30 PM
Insys Therapeutics (INSY) Lowered to Underweight at Piper Jaffray CompaniesInsys Therapeutics (INSY) Lowered to Underweight at Piper Jaffray Companies
www.americanbankingnews.com - March 9 at 11:24 PM
Ivy League Doctor Gets 4 Years in Prison for Insys Opioid Kickbacks - BloombergIvy League Doctor Gets 4 Years in Prison for Insys Opioid Kickbacks - Bloomberg
www.bloomberg.com - March 9 at 3:24 PM
Doctor in Insys opioid kickback scheme gets more than four years in prisonDoctor in Insys opioid kickback scheme gets more than four years in prison
finance.yahoo.com - March 9 at 3:24 PM
Ivy League Doctor Gets 4 Years in Prison for Insys Opioid KickbacksIvy League Doctor Gets 4 Years in Prison for Insys Opioid Kickbacks
finance.yahoo.com - March 9 at 3:24 PM
Drugmaker Insys reports bigger loss on lower Subsys sales - ReutersDrugmaker Insys reports bigger loss on lower Subsys sales - Reuters
www.reuters.com - March 9 at 6:01 AM
INSYS Therapeutics Reports Fourth Quarter and Full Year 2017 Results - GlobeNewswire (press release)INSYS Therapeutics Reports Fourth Quarter and Full Year 2017 Results - GlobeNewswire (press release)
globenewswire.com - March 9 at 6:01 AM
BRIEF-Insys Therapeutics Voting Trust Reports 58 Pct Stake In Insys As Of Feb 27 - ReutersBRIEF-Insys Therapeutics Voting Trust Reports 58 Pct Stake In Insys As Of Feb 27 - Reuters
www.reuters.com - March 9 at 6:01 AM
Drugmaker Insys reports bigger loss on lower Subsys salesDrugmaker Insys reports bigger loss on lower Subsys sales
finance.yahoo.com - March 9 at 6:01 AM
INSYS Therapeutics Reports Fourth Quarter and Full Year 2017 ResultsINSYS Therapeutics Reports Fourth Quarter and Full Year 2017 Results
finance.yahoo.com - March 9 at 6:01 AM
Drugmaker Insys loss widens on lower Subsys salesDrugmaker Insys loss widens on lower Subsys sales
finance.yahoo.com - March 9 at 6:01 AM
After-hours buzz: MAT, HAS, UNFI & moreAfter-hours buzz: MAT, HAS, UNFI & more
finance.yahoo.com - March 9 at 6:01 AM
Insys Therapeutics reports 4Q lossInsys Therapeutics reports 4Q loss
finance.yahoo.com - March 9 at 6:01 AM
Insys Therapeutics (INSY) Releases  Earnings Results, Misses Expectations By $0.47 EPSInsys Therapeutics (INSY) Releases Earnings Results, Misses Expectations By $0.47 EPS
www.americanbankingnews.com - March 8 at 9:12 PM

SEC Filings

Insys Therapeutics (NASDAQ:INSY) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Insys Therapeutics (NASDAQ:INSY) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Insys Therapeutics (NASDAQ INSY) Stock Chart for Thursday, April, 19, 2018

Loading chart…

This page was last updated on 4/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.